These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 23253764)

  • 1. Antiretroviral prophylaxis for sexual and injection drug use acquisition of HIV.
    Campbell JD; Herbst JH; Koppenhaver RT; Smith DK
    Am J Prev Med; 2013 Jan; 44(1 Suppl 2):S63-9. PubMed ID: 23253764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Where to deploy pre-exposure prophylaxis (PrEP) in sub-Saharan Africa?
    Verguet S; Stalcup M; Walsh JA
    Sex Transm Infect; 2013 Dec; 89(8):628-34. PubMed ID: 23912819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preexposure prophylaxis for the prevention of HIV transmission to women.
    Aaron E; Cohan D
    AIDS; 2013 Jan; 27(1):F1-5. PubMed ID: 22914582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of pre-exposure prophylaxis for HIV: a review.
    Schackman BR; Eggman AA
    Curr Opin HIV AIDS; 2012 Nov; 7(6):587-92. PubMed ID: 23076124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Animal models of antiretroviral prophylaxis for HIV prevention.
    García-Lerma JG; Heneine W
    Curr Opin HIV AIDS; 2012 Nov; 7(6):505-13. PubMed ID: 22964889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Untangling the cost-effectiveness knot: who is oral antiretroviral HIV pre-exposure prophylaxis really for?
    Hankins CA
    Expert Rev Pharmacoecon Outcomes Res; 2014 Apr; 14(2):167-70. PubMed ID: 24552641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral pre-exposure prophylaxis for HIV prevention.
    García-Lerma JG; Paxton L; Kilmarx PH; Heneine W
    Trends Pharmacol Sci; 2010 Feb; 31(2):74-81. PubMed ID: 19963288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attitudes towards new HIV biomedical prevention technologies among a cohort of HIV-negative gay men in Sydney, Australia.
    Poynten IM; Jin F; Prestage GP; Kaldor JM; Imrie J; Grulich AE
    HIV Med; 2010 Apr; 11(4):282-8. PubMed ID: 20015220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ethics of ARV based prevention: treatment-as-prevention and PrEP.
    Haire B; Kaldor JM
    Dev World Bioeth; 2013 Aug; 13(2):63-9. PubMed ID: 23594312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Knowledge, attitudes, and likelihood of pre-exposure prophylaxis (PrEP) use among US women at risk of acquiring HIV.
    Auerbach JD; Kinsky S; Brown G; Charles V
    AIDS Patient Care STDS; 2015 Feb; 29(2):102-10. PubMed ID: 25513954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The promise of pre-exposure prophylaxis with antiretroviral drugs to prevent HIV transmission: a review.
    Hankins CA; Dybul MR
    Curr Opin HIV AIDS; 2013 Jan; 8(1):50-8. PubMed ID: 23201856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The performative function of expectations in translating treatment to prevention: the case of HIV pre-exposure prophylaxis, or PrEP.
    Rosengarten M; Michael M
    Soc Sci Med; 2009 Oct; 69(7):1049-55. PubMed ID: 19695756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preexposure prophylaxis (PrEP) of HIV infection in France: a nationwide cross-sectional study (PREVIC study).
    Rosenthal E; Piroth L; Cua E; Joulié A; Ravaux I; Chauveau M; Lacombe K; Cotte L; Bonnard P; Weiss L; Longuet M; Pradier C; Cacoub P;
    AIDS Care; 2014 Feb; 26(2):176-85. PubMed ID: 23756091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence to preexposure chemoprophylaxis: the behavioral bridge from efficacy to effectiveness.
    Amico KR
    Curr Opin HIV AIDS; 2012 Nov; 7(6):542-8. PubMed ID: 22964887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Considerations regarding antiretroviral chemoprophylaxis in MSM.
    Poynten IM; Zablotska I; Grulich AE
    Curr Opin HIV AIDS; 2012 Nov; 7(6):549-56. PubMed ID: 22918448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-exposure prophylaxis (PrEP) for HIV infection: results of a survey of HIV healthcare providers evaluating their knowledge, attitudes, and prescribing practices.
    Tellalian D; Maznavi K; Bredeek UF; Hardy WD
    AIDS Patient Care STDS; 2013 Oct; 27(10):553-9. PubMed ID: 24053478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Awareness of, usage of and willingness to use HIV pre-exposure prophylaxis among men in downtown Toronto, Canada.
    Leonardi M; Lee E; Tan DH
    Int J STD AIDS; 2011 Dec; 22(12):738-41. PubMed ID: 22174057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suboptimal awareness and comprehension of published preexposure prophylaxis efficacy results among physicians in Massachusetts.
    Mimiaga MJ; White JM; Krakower DS; Biello KB; Mayer KH
    AIDS Care; 2014; 26(6):684-93. PubMed ID: 24116985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do You PrEP? A Review of Primary Care Provider Knowledge of PrEP and Attitudes on Prescribing PrEP.
    Turner L; Roepke A; Wardell E; Teitelman AM
    J Assoc Nurses AIDS Care; 2018; 29(1):83-92. PubMed ID: 29274655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Review of Approaches Used to Increase Awareness of Pre-exposure Prophylaxis (PrEP) in the United States.
    Sophus AI; Mitchell JW
    AIDS Behav; 2019 Jul; 23(7):1749-1770. PubMed ID: 30306434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.